Status:
COMPLETED
Melatonin for Migraine Prevention
Lead Sponsor:
Nordlandssykehuset HF
Collaborating Sponsors:
University of Tromso
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The circadian system with its centre in the hypothalamus is involved in migraine pathophysiology. Whether it plays a pivotal role is not clarified. The investigators postulate that a destabilized circ...
Eligibility Criteria
Inclusion
- Patients between 18 and 65 years, both male and females.
- Migraine present for at least 1 year and fulfilling diagnostic criteria that conform to those of the International Headache Society (HIS) \[2\] but otherwise healthy.
- Attacks of migraine should occur 4-6 times per month, there should be no regular use of other drugs, and the patient has to be able to differentiate between migraine headache and non-migrainous headache.
- Preventive drugs for migraine should not have been used the last three months.
- Conventional acute attack treatment is accepted, but not sporadic use of other drugs like hypnotics and anxiolytics.
- Residence of North-Norway.
Exclusion
- Medication overuse headache, chronic migraine.
- Pregnant and breast feeding women.
- Patient with either serious co-morbidity or conditions requiring medical treatment or caution.
- Psychiatric disease.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00849511
Start Date
February 1 2009
End Date
October 1 2009
Last Update
September 25 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Departement of Neurology, NLSH HF
Bodø, Norway, 8092
2
Departement of Neurology
Tromsø, Norway, 9037